The Baroda BNP Paribas Health and Wellness Fund Direct Growth has demonstrated robust performance across multiple timeframes, significantly outperforming category averages. According to the latest data, the fund has delivered +17.2% returns over 3 months, +11.1% over 6 months, and +9.57% over 1 year, substantially exceeding the equity sectoral category averages. The fund currently maintains an Asset Under Management (AUM) of ₹544.17 crore and has a Latest NAV as of July 9, 2026 of ₹10.65. The fund ranks #25 in India by total assets and is rated Very High risk with a minimum SIP investment of ₹500 and lumpsum investment of ₹1,000.
The fund's management structure has been reorganized with Rohan Korde and Sanjay Chawla being replaced by Rohan Korde and Ankeet Pandya as co-managers. As per the fund house, this change took effect from July 10, 2026, marking a significant shift in the fund's operational structure. The transition maintains continuity with Rohan Korde remaining as part of the management team, while Ankeet Pandya joins as the new co-manager, ensuring that the fund continues to benefit from experienced fund management expertise while introducing fresh perspectives to the investment strategy.
The fund's portfolio is strategically focused on the healthcare and pharmaceutical sector, with Sun Pharmaceutical Industries Ltd being the largest holding at 9.09% of assets. Other major holdings include Lupin Ltd at 5.83%, Laurus Labs Ltd at 5.76%, and Abbott India Ltd at 5.43%. The fund also maintains significant exposure to Apollo Hospitals Enterprise Ltd at 4.66%, Torrent Pharmaceuticals Ltd at 5.27%, and Ipca Laboratories Ltd at 5.18%. The scheme is designed to provide long-term capital appreciation by investing predominantly in equity and equity-related instruments of pharma and healthcare companies, with the fund benchmarked against the BSE Healthcare Total Return Index.
The fund operates with specific exit load provisions for investors. For units exceeding 10% of the investment, 1% will be charged for redemption within 1 year. If investors redeem within one year, returns are taxed at 20%. For redemptions after one year, returns exceeding ₹1.25 lakh in a financial year are taxed at 12.5%. The fund's current NAV of ₹10.65 reflects the latest pricing as of July 9, 2026, providing investors with accurate valuation information for their holdings.
